The period for CME/CE credit for this activity has expired.

This activity has expired. Thank you for using Continue to check our activities page for additional online CME offerings .

Post-Test - Peak Issues: Clinical Use Of Incretin-Based Therapies To Promote PPG Control In Type 2 Diabetes

INSTRUCTIONS: Select the most appropriate response. To receive credit, participants must earn a score of 70% or higher.

1. A patient’s ______ level provides a record of average blood glucose levels over several months, but it is not a good indicator of glycemic variability.
A: A1C
B: Fasting plasma glucose (FPG)
C: Postprandial plasma glucose (PPG)
D: Preprandial plasma glucose (PrePG)

2. PPG is typically measured _______ following a meal.
A: immediately
B: 1-2 hours
C: 5-6 hours
D: 7-8 hours

3. PPG levels have a relatively __________ influence on overall glycemic control at near normal plasma glucose levels and contribute approximately _________ when A1C is < 7.3%.
A: small, 10%
B: small, 30%
C: large, 50%
D: large, 70%

4. The American Diabetes Association (ADA) recommends a therapeutic PPG target of _________, and the American Association of Clinical Endocrinologists (AACE) recommends _____________.
A: < 200 mg/dL, < 180 mg/dL
B: 70-130 mg/dL, < 110 mg/dL
C: < 180 mg/dL, < 140 mg/dL
D: < 160 mg/dL, < 120 mg/dL

5. A study by Bonora et al revealed that _______ of patients with type 2 diabetes experience PPG levels > 160 mg/dL.
A: < 10%
B: < 50%
C: > 60%
D: > 90%

6. Postprandial hyperglycemia in the range of 140 to 200 mg/dL is referred to as impaired glucose tolerance (IGT) and is considered to be a prediabetic state with a risk of progression to diabetes of ________.
A: 30% over 1 year
B: 10% over 3 years
C: 30% over 3 years
D: 30% over 5 years

7. Agents that ameliorate PPG excursions may provide cardiovascular benefits as demonstrated by their ability to _________.
A: slow the progression of atherosclerosis
B: increase inflammation
C: increase blood pressure
D: decrease A1C

8. Postprandial hyperglycemia is a consequence of several physiologic abnormalities including insulin resistance, decreased β-cell function, and ________________.
A: increased insulin secretion
B: slowed gastric emptying
C: impaired glucagon suppression
D: decreased hepatic glucose production

9. Which of the following is not an agent or class of agents that targets PPG levels?
A: α-glucosidase inhibitors
B: fast-acting insulin analogs
C: incretin-based therapies
D: metformin

10. Incretin-based therapies improve PPG control by __________________.
A: suppressing glucagon secretion
B: accelerating gastric emptying
C: decreasing postprandial insulin release
D: inhibiting α-glucosidase